drugset / Trial / NCT00555035

GSK1349572 First Time in Human Study

NCT00555035

Phase 1 Completed 20 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

To determine safety, tolerability and pharmacokinetics of GSK1349572

Timeline

Start
2007-11
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Dolutegravir Other / unclassified

Indications

No indication recorded.